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Thymic regulatory T cells (tTregs) and induced regulatory T cells (iTregs) suppress murine acute graft-versus-host disease (GVHD)
. Previously, we demonstrated that the plasmacytoid dendritic cell indoleamine 2,3-dioxygenase (IDO) fosters the in vitro development of human iTregs via tryptophan depletion and kynurenine (Kyn) metabolites. We now show that stimulation of na€ ıve CD4 + T cells in low tryptophan (low Trp) plus Kyn supports human iTreg generation. In vitro, low Trp + Kyn iTregs and tTregs potently suppress T effector cell proliferation equivalently but are phenotypically distinct. Compared with tTregs or T effector cells, bioenergetics profiling reveals that low Trp + Kyn iTregs have increased basal glycolysis and oxidative phosphorylation and use glutaminolysis as an energy source. Low Trp + Kyn iTreg viability was reliant on interleukin (IL)-2 in vitro. Although in vivo IL-2 administration increased low Trp + Kyn iTreg persistence on adoptive transfer into immunodeficient mice given peripheral blood mononuclear cells to induce GVHD, IL-2-supported iTregs did not improve recipient survival. We conclude that low Trp + Kyn create suppressive iTregs that have high metabolic needs that will need to be addressed before clinical translation.
Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is limited by immune cell-mediated graft-versus-host disease (GVHD) (1) , which is significant in 40-70% of recipients, with skin, liver, and gut representing major GVHD target organs (2) . Immunoregulation is critical for maintaining homeostasis. Regulatory T cells (Tregs) are required to suppress self-reactive lymphocytes and can develop in the thymus (tTregs) or be induced in vivo (peripheral Tregs) or in vitro (iTregs). Adoptive Treg transfer is effective in preventing autoimmunity, organ rejection, and GVHD in preclinical models (1, 3) . We completed first-in-human clinical trials of ex vivo expanded umbilical cord blood (UCB) CD4 + 25 hi tTregs in patients receiving HSCT (4, 5) . As predicted by results with allogeneic and xenogeneic murine models (6) , high tTreg doses (1 9 10 8 /kg, or~1:1 tTregs: UCB T cells) were needed to effectively ameliorate grade II-IV GVHD (9% vs. 45% for matched controls, p < 0.05) (5), thus requiring large-scale expansion with retention of function from a relatively rare UCB tTreg population.
While third-party UCB tTregs fit nicely into a UCB clinical trial, peripheral blood (PB) Tregs from histocompatible family members are more amenable for solid organ graft studies and HSCT by enabling closer minor histocompatibility antigen matching. Because expanding human PB tTregs can result in loss of suppression due to the proliferative advantage of contaminating T effector cells (Teffs) after purification, we explored clinically relevant approaches to generate iTregs. iTreg therapeutics are of interest because the cotransfer of both tTregs and iTregs in a rodent inflammatory bowel disease model was shown to be necessary for optimal disease suppression (7) , suggesting that future trials could combine tTregs and iTregs. We found that clinically relevant numbers of iTregs (>200 9 10 9 ) could be induced via in vitro expansion for 14 days in the presence of TGFb and rapamycin (8) . Because murine Tregs induced by food allergens in the gut, a primal GVHD target organ, through TGFb-secreting dendritic cells (DCs) can be reprogrammed into Teffs (9), we sought iTreg approaches that might result in high yields, potency, and stability and that do not rely on TGFß.
Previously, we observed that human Tregs can be induced by plasmacytoid DCs (pDCs) through indoleamine 2,3-dioxygenas (IDO)-mediated depletion of tryptophan (Trp) or by exposure to immunosuppressive kynurenines (Kyn), produced as catabolites of Trp metabolism (10, 11) . IDO is implicated in maternal-fetal acceptance (12) , tumor immunity (13) , autoimmunity (14, 15) , and alloimmunity reactions, such as GVHD (16, 17) . Exposure of murine tTregs to IDO in vitro or in vivo markedly enhances their suppressor function, "supercharging" their potency (18) (19) (20) (21) . Because pDCs are rare and difficult to purify and expand, we sought to determine whether optimally suppressive iTregs could be generated by using conditions that mimicked pDC support (i.e. low Trp + Kyn) amenable for clinical translation.
We report that clinically relevant numbers of iTregs can be generated by stimulating na€ ıve human CD4 + T cells with good manufacturing practices (GMP)-compliant artificial antigen-presenting cells in media containing low Trp + Kyn. These iTregs are as suppressive as tTregs in vitro. However, bioenergetics profiling showed that, unlike tTregs, low Trp + Kyn iTregs displayed remarkably active oxidative phosphorylation, driven in part through glutamine catabolism. Low Trp + Kyn iTregs also had higher glycolytic metabolism and were more sensitive to IL-2 deprivation, known to support glycolysis (22) . Low Trp + Kyn iTregs had decreased viability in vitro and in vivo. Ultra-low-dose IL-2, which was unable to sustain iTreg persistence in vivo and recipient survival, was not significantly increased compared with the level in GVHD mice receiving no iTregs. These results demonstrate that clinically relevant numbers of highly suppressive low Trp + Kyn iTregs can be generated but that the in vivo persistence of iTregs after adoptive transfer will need to be improved by overcoming their higher metabolic needs or by optimizing IL-2 supplementation in vivo to achieve GVHD prevention in vivo.
Materials and Methods
Cell purification and culture were isolated from the flow-through: remaining CD25 int cells were depleted by using a high-dose, anti-CD25 step, and then CD45RA fraction was purified through positive selection by using anti-CD45RA microbeads. Bead incubations and washes were carried out as specified by the manufacturer (30 min at room temperature for cGMP-grade beads). . Recombinant IL-2 (300 IU/mL, Proleukin, San Diego, CA) was added (on day 2 for tTregs and day 0 for all other cells) and maintained throughout culture. For tTregs, rapamycin (Rapammune; Wyeth-Ayerst, Princeton, NJ) was added at 109 nmol/L on day 0 and with media supplementation. Low Trp + Kyn iTreg cultures were treated with five kynurenines (10 lmol/L each) added on day 0 and maintained throughout culture.
Suppression assays
Suppression was assessed by using a 5-carboxyfluorescein-diacetatesuccinimide ester (CFSE) inhibition assay (24) . Peripheral blood mononuclear cells (PBMCs) were purified, labeled with CFSE (InVitrogen, Carlsbad, CA), and stimulated with anti-CD3 mAb-coated beads (ThermoFisher Scientific, Waltham, MA) in 96-well round-bottomed plates with or without cultured tTregs or iTregs (Tregs:PBMCs ratios of 1:4-1:16). Assays were harvested on day 4 and stained with anti-CD4 and/or anti-CD8 mAbs, and then data were acquired by using FACScalibur or LSRII (both BD Biosciences, San Jose, CA). Data were analyzed by using the proliferation platform in FlowJo (Treestar, Ashland, OR), and suppression was determined from the division index. Figure 1D ), with significantly higher (~10-fold) CD25 levels in low Trp + Kyn iTregs versus tTregs ( Figure 1E ).
Results

Expansion
tTregs potently suppressed CD8 + T cell division by using a CFSE-based proliferation assay ( Figure 1F ). CD4 Figures  S3A-D) . In contrast to tTregs, low Trp + Kyn iTregs did not show Foxp3 Treg-specific demethylated region hypomethylation (25) , nor did they express Helios, an Ikaros family transcription factor associated with tTreg origin ( Figures S3E and F) (26) . tTreg expression of CD39 and adenosine production has been linked to suppressive function (27) (28) (29) . While low Trp + Kyn iTregs expressed CD39, expression was not significantly higher than that of Teffs, which had minimal suppressive function ( Figure S2G ). To determine whether suppression was contact dependent, assays were performed in transwell plates with expanded cells either in the lower chamber with the PBMCs or separated by the transwell membrane. tTreg suppression was greatly decreased when contact was prevented. Close contact was required for low Trp + Kyn iTreg suppression, whether measured by division index or number of CD8 + cells remaining (a measure for cytolysis-mediated suppression) (Figures S2H and I, respectively).
Because the goal is to use low Trp + Kyn iTregs as adoptive cellular therapy in patients with normal Trp levels and lacking Kyn, we assessed the stability and suppressive function of the low Trp + Kyn iTregs recultured for the final 3 days in media with normal Trp (25 mmol/L) and no Kyn. As shown in Figure S4 , no significant change was observed in Foxp3 or CD25 expression, and cultures maintained suppressive function, suggesting that adoptive transfer of low Trp + Kyn iTregs would retain suppressor function in vivo.
Low Trp + Kyn iTregs have higher levels of oxidative phosphorylation than tTregs or Teffs Metabolism is intimately linked to T cell differentiation and function (22) . The metabolic program of low Trp + Kyn iTregs was of particular interest given their generation under conditions of essential amino acid (Trp) depletion. Both the basal and maximal respiratory capacities (oxygen consumption rate [OCR]) of iTregs were significantly higher than those of tTreg or Teff cultures (Figure 2A) . Increased OCR did not result from increased mitochondria, as all three cultures stained similarly with MitoTracker Green (ThermoFisher), which measures mitochondrial mass ( Figure 2B ).
Low Trp + Kyn iTregs also have increased glucose consumption and production of lactate compared with tTregs or Teffs Extracellular acidification rate (ECAR) is a measure of aerobic glycolysis, and it results from lactate and pyruvate export. As expected, Teffs had a significantly higher ECAR than tTregs, both under basal conditions and at maximal glycolytic capacity ( Figure 3A) . Unexpectedly, low Trp + Kyn iTregs had an even higher basal ECAR and a similar maximal glycolytic capacity as those of Teffs. Notably, this metabolic profile (increased oxidative phosphorylation [OXPHOS] and glycolysis) is shared with rodent T cells proliferating in response to alloantigens during GVHD (30) . Consistent with increased ECAR, low Trp + Kyn iTregs expressed higher levels of the glucose transporters Glut-1 and Glut-2 than did tTregs or Teffs ( Figure 3B ). Low Trp + Kyn iTregs consumed significantly more glucose and excreted more lactate compared with Teffs, while tTregs excreted the lowest amounts of lactate (2.8-and 1.9-fold vs. low Trp + Kyn iTregs and Teffs, respectively) ( Figures 3C and D) .
Low Trp + Kyn iTregs display higher rates of glutamine oxidation than tTregs or Teffs CD4 T cells can produce energy via glutaminolysis (31), a process in which glutamine is catabolized to glutamate and then a-ketoglutarate, where it enters the tricarboxylic acid cycle to contribute to OXPHOS (32) . To assess whether glutaminolysis contributed to high basal OXPHOS in low Trp + Kyn iTregs, we measured glutamine consumption at 24 h from the same anti-CD3/28 mAb bead-stimulated samples used for glucose consumption. While glutamine levels decreased 130 lmol/L in Teff cultures, the decrease was 330 lmol/L in low Trp + Kyn iTreg cultures, indicating that iTreg cultures are more actively using glutaminolysis for energy ( Figure 4A tTregs are expanded in clinically defined media that include high glutamine levels; thus, these assays are not applicable. In addition to intracelluilar glutamine transport, the large neutral amino acid transporter (LAT1, a heterodimer of CD98 and SLC3A2) can also use intracellular glutamine as an exchange partner to drive the import of Trp (33) . Low Trp + Kyn iTreg CD98 expression was sevenfold and fourfold higher than that on tTregs and Teffs, respectively ( Figure 4B ). Low Trp + Kyn iTregs expressed fivefold higher levels of GLS2, the mitochondria-associated glutaminase responsible for converting glutamine to glutamate, compared with Teffs ( Figure 4C ).
Fatty acid esterification and intracellular triglycerides support low Trp + Kyn iTreg metabolism tTregs and memory CD8 T cells (Tmems) use fatty acid (FA) oxidation (FAO) to drive energy production (34) . Compared with Teffs, tTregs had increased expression of two key enzymes involved in shuttling FAs to the mitochondria (carnitine palmitoyltransferase I a [CPT1a] and acyl-coenzymeA synthetases 3 [ACSL3]) and of DGAT1, a triacylglycerol (TAG) synthase, which converts diacylglycerol to TAG, a critical substrate for FAO (35) (Figure S5 ). FAs used to fuel CD8 Tmems are not derived from extracellular sources but rather through a futile cycle of de novo FA synthesis (FAS) followed by FAO (36); long-chain FA uptake is lower in CD8 Tmems than in CD8 Teffs (37) . Similar to CD8 Tmems, tTregs had decreased signs of FAS compared with CD4 Teffs, including low rate of FA uptake (measured with the use of 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (BoDipy C 1 , C 12 ; ThermoFisher Scientific, Waltham, MA) a fluorescent FA analog) and decreased expression of SLC27A2, a long-chain FA transport molecule ( Figure 5 ). In contrast to tTregs and CD8 Tmems, low Trp + Kyn iTregs exhibited a reciprocal phenotype, with increased FA uptake and SLC27A2 expression and decreased expression of CPT1a and ACSL3.
Human and murine CD8 Tmem survival and selfrenewal were recently shown to be dependent on molecules involved in TAG synthesis (38) . Specifically, CD8 T cells that lacked the glycerol channel aquaporin 9 (AQP9) or were treated with an AQP9-specific inhibitor had impaired memory responses, and AQP9 -/-Tmem survival was rescued by overexpression of AQP9. AQP9 expression, driven by IL-7 receptor signaling in CD8 Tmems, was very low to absent in tTregs, which have greatly reduced IL-7 receptor expression ( Figure 5C ). AQP9 expression, observed in Teffs, was highest in low Trp + Kyn iTregs. In summary, while the predominant phenotype of tTregs is FAO, low Trp + Kyn iTregs are more closely linked with FAS. Low Trp + Kyn iTreg adoptive transfer transiently suppresses clinical manifestations of xenogeneic GVHD but not to a sufficient magnitude to prolong survival To determine whether low Trp + Kyn iTregs could suppress T cell activation in vivo, a xenogeneic model of GVHD was used in which human CD4 + 25 ++ and CD4 + 25 -45RA + T cells were purified from the same donor, expanded in vitro as tTregs and low Trp + Kyn iTregs, and transferred into immunodeficient NOD-SCIDIL2rgc (NSG) mice along with HLA-A2-mismatched PBMCs (8) . tTregs and low Trp + Kyn iTregs were ≥75% CD25 + Foxp3 + and were highly suppressive in vitro (Figure 6A ). In this model, disease severity correlates with the PB expansion of human PBMC-derived CD4 + and CD8 + T cells (24) . To assess PBMC-derived T cell expansion, recipients were bled on day 13, and PBMCs stained for human CD45, CD4, CD8, and HLA-A2-and PBMCderived (HLA-A2 + ) T cells were counted ( Figure 6B Tregs (HLA-A2 -CD4 + ) were enumerated from day-13 PB, before pathological injury. Results from mice receiving PBMCs only, and thus no HLA-A2 -cells, defined the assay limit of detection. As shown in Figure 6D , while the number of tTregs in PB was 10-fold that of background, low Trp + Kyn iTregs were not higher than background, suggesting their lack of efficacy may be due to diminished viability.
Low Trp + Kyn iTregs are highly dependent on IL-2 for survival IL-2 signaling supports glycolysis (22) . Because low Trp + Kyn iTregs express 10-fold higher levels of CD25 than tTregs, low Trp + Kyn iTregs may be more sensitive to cytokine withdrawal-induced apoptosis (39) if IL-2 bioavailability is limiting in vivo. To assess the effects of IL-2 depletion on tTreg, low Trp + Kyn iTreg, and Teff cell viability, cultures were harvested on day 14 and were then cultured for an additional 7 days in fresh media containing 300 U/mL (normal) or 30 U/mL IL-2 (low). While similar numbers were recovered from tTreg and Teff cultures grown in 300 U/mL and 30 U/mL of IL-2, low Trp + Kyn iTreg recovery was decreased fivefold ( Figure S7 ), confirming that low Trp + Kyn iTregs are more dependent on high-dose IL-2 than are tTregs or Teff. We compared low Trp + Kyn iTreg cultures expanded with 300 versus 1000 U/mL of IL-2 to determine whether decreased viability observed in low Trp + Kyn iTreg cultures resulted from a suboptimal IL-2 concentration, but we observed no concentration-dependent ) and Glut-2 expression on cultured cells. The indicated cells were restimulated for 24 h with aCD3/28 beads, and, after harvest, the supernatants were assayed for the consumption of glucose (C) and the production of lactate (D). Note that tTregs are expanded in clinically defined media that include high levels of glucose, and thus these assays are not applicable. CFSE, carboxyfluorescein diacetate succinimide ester; ECAR, extracellular acidification rate; FCCP, fluorocarbonyl cyanide phenylhydrazone; iTreg, induced regulatory T cell; Kyn, kynurenines; MFI, mean fluorescent intensity; NA, not applicable; PB,peripheral blood; Teff, effector T cell; tTreg, thymic regulatory T cell; Trp, tryptophan. difference in expansion, phenotype, or suppressive function (data not shown).
Ultra-low-dose IL-2 improves GVHD survival in mice treated with low Trp + Kyn iTregs but does not increase overall recipient survival Clinical trials have now shown that patients treated with ultra-low-dose IL-2 have increased Treg numbers (40) (41) (42) (43) . To determine whether ultra-low-dose IL-2 could enhance low Trp + Kyn iTreg persistence and efficacy, tTregs and low Trp + Kyn iTregs were purified from the same donor, expanded in vitro ( Figure 7A ), and injected with HLA-A2-mismatched PBMCs (15 9 10 6 each) into NSG mice. A subset of each cohort was given ultra-low-dose IL-2 (25 000 U/day for 14 days). To assess persistence, animals were bled on days 7 ( Figure S8A ) and 14 ( Figure 7B ) and Tregs and Teffs were counted ( Figure 7B ). Low Trp + Kyn iTregs were present in similar numbers to tTregs on day 7. Ultra-low-dose IL-2 significantly increased the number of day-7 PB low Trp + Kyn iTregs, although iTregs were not present in higher numbers than tTregs regardless of IL-2 administration. Importantly, low Trp + Kyn iTregs were not found on day 14, in sharp contrast to tTreg cohorts. Day-14 PB CD4 + and CD8 + Teffs each were significantly lower in tTreg groups compared with all other cohorts, whereas low Trp + Kyn iTregs did not favorably affect either day-14 Teff subset compared with PBMC controls. Reflective of day-14 Teff numbers, in vitro expanded tTregs significantly prolonged survival compared with animals receiving PBMCs only ( Figure 7C ), whereas low Trp + Kyn iTreg adoptive transfer did not. Ultra-low-dose IL-2 significantly decreased survival of mice receiving PBMCs only or PBMCs plus low Trp + Kyn iTregs (p ≤ 0.001 for both). IL-2 decreased the survival of mice receiving PBMCs plus tTregs, albeit not significantly (median survival 53 vs. 38 days). IL-2 significantly increased weight loss and clinical scores from day 11 until time of death (day 15 for low Trp + Kyn iTregs and day 18 for PBMCs only) ( Figures S8A and B) . Consistent with increased disease severity, IL-2 increased the number of day-14 PB CD4 + and CD8 + T cells ( Figure 7D ) in mice receiving either no iTregs or low Trp + Kyn iTregs. In contrast, mice receiving tTregs had >20-fold fewer PB CD4 + and CD8 + T cells, and IL-2 had no effect on PBMC-derived T cell number. The ratio of PB CD4 + to CD8 + T cells was skewed toward CD8 T cells in mice receiving low Trp + Kyn iTregs, exacerbated further by IL-2 treatment. In aggregate, these data indicate that ultra-low-dose IL-2 favored CD4 + and CD8 + Teff expansion without sustaining low Trp + Kyn iTreg persistence, resulting in a failure of iTregs and a reduction in tTregs to prevent GVHD.
Low Trp + Kyn iTregs have decreased expression of bcl-2, increased superoxide production, and decreased viability in vitro Because decreased low Trp + Kyn iTreg in vivo persistence and efficacy could be due to an overall "lack of fitness" of low Trp + Kyn iTregs, we assessed the viability of cultures on day 14 by using flow cytometry. Low Trp + Kyn iTregs had significantly reduced viability compared with tTreg and Teff cultures ( Figure 8A ). In keeping with increased basal OXPHOS, low Trp + Kyn iTregs had increased mitochondrial membrane potential relative to tTregs and Teff, which can lead to increased formation of reactive oxygen species (ROS) (Figures 8B and C) . Kyn have been linked to glutathione depletion, increased formation of ROS, and apoptosis in activated T cells (44) . To assay ROS generation, we stained cells with dihydroethidine (DHE), a redoxsensitive dye specific for superoxide (45) . ROS generation was observed in <8% of tTregs and Teffs ( Figure 8D ), whereas >25% of low Trp + Kyn iTregs had demonstrable DHE staining, indicating that decreased viability may be linked to oxidative stress.
Proapoptotic and antiapoptotic members of the bcl-2 family are key mediators of the mitochondrial apoptotic pathway and can have a significant impact on viability. Bax induces mitochondrial outer membrane permeabilization and is allosterically regulated by Bim (activation) and Bcl-2/Bcl-xL (inhibition), which compete for a common binding site (46) . To determine whether this pathway contributes to decreased low Trp + Kyn iTreg viability, the expression of these bcl family members was determined ( Figures 8E-H, respectively) . tTregs express significantly higher levels of Bax than do low Trp + Kyn iTregs and Teffs but, as we reported previously, they maintain a favorable ratio of proapoptotic to antiapoptotic proteins, expressing low levels of Bim and high levels of Bcl-2 and Bcl-xL (24). In contrast, Teffs had fivefold higher Bim expression and lower expression of Bcl-2 and Bcl-x (3.4-and 2.1-fold, respectively). Like tTregs, low Trp + Kyn iTregs expressed low levels of Bim, suggesting that decreased viability may not be due to mitochondrial outer membrane permeabilization. However, they also expressed significantly less Bcl-2, Bcl-xL, and Bax than tTregs. In conclusion, determining the pathways that cause decreased low Trp + Kyn iTreg viability and identifying ways to promote iTreg survival via appropriately regulating Bcl-2 pathway members will be critical steps for clinical translation.
Discussion
Because we previously showed that IDO expressed by pDCs induces Treg function in human T cells in vitro (10, 16, 17) , we sought to determine whether suppressive iTregs could be generated from na€ ıve human CD4 + T cells by using conditions that mimicked pDCs (i.e. low Trp + Kyn) that would be amenable for clinical translation. Here, we show that na€ ıve T cells expanded in conditions of low Trp + Kyn are as suppressive as tTregs. Low Trp + Kyn iTregs have advantages over tTregs, including simpler purification, and the initial yield after purification is about sevenfold higher than that of PBMC tTregs and 400-fold higher than that of UCB tTregs. Consequently, therapeutic yield would be~100-fold higher than reported in initial studies for the direct infusion of PBMC tTregs (5, 47, 48) . Biochemically, we found that na€ ıve + cells expressing CD4. n = 7 mice per group. GVHD, graft-versus-host disease; iTreg, induced regulatory T cell; Kyn, kynurenines; MFI, mean fluorescent intensity; NSG, NOD-SCID-IL2rgc; PBMC, peripheral blood mononuclear cell; Teff, effector T cell; tTreg, thymic regulatory T cell; Trp, tryptophan.
CD4
+ T cells expanded in the presence of low Trp + Kyn displayed a metabolic profile unlike that of CD4 + or CD8 + T cells in the literature, in that they were very active in glycolysis, OXPHOS, glutaminolysis, and FAS.
One of the most striking features of low Trp + Kyn iTreg metabolism is greatly increased glutaminolysis. While it was unclear the precise mechanisms responsible driving this pathway in low Trp + Kyn iTregs, which had very low expression of the transcription factors most closely linked to glutaminolysis (p53 and c-myc) (32), engagement of this pathway would have several benefits. First, glutaminolysis produces a variety of amino acids, which prevents GCN2 (general control nonderepressible 2) activation and suppresses the integrated stress response. Glutaminolysis is uniquely suited for high levels of OXPHOS in that glutamine metabolic pathways lead to products that directly control ROS levels. Specifically, glutamine input is the ratelimiting step for the synthesis of glutathione and glutaminolysis generates nicotinamide adenine dinucleotide phosphate (NADPH), which reduces oxidized glutathione disulfide to glutathione. NADPH is also necessary for FAS (32) and fits with the FAS-profile displayed by low Trp + Kyn iTregs (increased expression of molecules involved in uptake or transport of FA and glycerol), distinct from the FAO profile associated with tTregs (increased expression of molecules involved in shuttling FA to the mitochondria or synthesizing triacylglycerides). Low Trp + Kyn iTreg metabolism appears to be skewed to help them survive in conditions of low Trp. Specifically, arylhydrocarbon ligands have previously been shown to upregulate CD98, a subunit of the LAT1 antiporter (49) . Becausee the LAT1 antiporter is capable of exchanging glutamine for Trp (33) , it is likely that increased glutaminolysis and CD98 expression maximize Trp and leucine uptake (50) to maintain their viability and serve as an energy source.
Decreased low Trp + Kyn iTreg survival even with ultralow-dose IL-2 may result from ROS-driven mitochondrial permeability transition (51) or apoptosis controlled by Bcl-2 family members (46) . This process may be exacerbated by activated, CD25 + Teffs that receive exogenous IL-2 and produce proinflammatory cytokines. While in vitro and in vivo survival is the primary limitation for the clinical translation of low Trp + Kyn iTregs, it is important to note that there are many drugs available that inhibit these processes, including cyclophilin-D/GSK3b inhibitors, antioxidants (e.g. N-acetylcysteine), and z-VAD-fmk, to inhibit caspase-3 activation. In conclusion, this work defines the clinical-scale production of iTregs induced in vitro through the expansion of Teffs under conditions of low Trp + Kyn that are as suppressive in vitro as tTregs. A better understanding of low Trp + Kyn iTreg metabolic demands and survival requirements is needed before clinical translation.
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Data S1: Supplemental materials and methods. -45RA + ) were purified from peripheral blood by using magnetic beads and purity was assessed with flow cytometry. Representative example and summary for T cell (CD4 and CD25) (A) and tTreg (CD127 and Foxp3) (B) markers.
iTreg, induced regulatory T cell. , and IL-4 (C) were assessed by intracellular cytokine staining. To assess the ability of cultured cells to produce IL-10, cultures were restimulated overnight with CD3/28 beads and, after harvest, the supernatants were tested for IL-10 (LD, limit of detection for the assay). (E) Methylation status of 10 CpG sites within the Treg-specific demethylated region was determined for cultures of tTreg and na€ ıve T cells cultured with or without low Trp + Kyn by using bisulfite sequencing (n = 4). (F) Helios expression in cultures of tTreg and na€ ıve T cells cultured with or without low Trp + Kyn. To determine whether suppression was contact dependent, cultured cells were incubated with CFSE-labeled PBMCs in transwell plates with cultured cells either in the lower well with the PBMCs (cell contact) or in the upper chamber (transwell). Suppression of CD8 + T cell proliferation was assessed by CFSE dilution (G) and by directly enumerating CD8 + T cells (H). n = 3-5 experiments. CFSE, carboxyfluorescein diacetate succinimide ester; IFN, interferon; IL, interleukin; iTreg, induced regulatory T cell; Kyn, kynurenines; MFI, mean fluorescent intensity; PBMC, peripheral blood mononuclear cell; Teff, effector T cell; TMRM, tetramethylrhodamine methyl ester; tTreg, thymic regulatory T cell; Trp, tryptophan. To assess cytokine dependence, PB tTreg, low Trp + Kyn iTreg, and Teff cultures were split on day 14 into their respective media with either normal (300 U/mL) or limiting (30 U/mL) amounts of IL-2 and recultured for an additional 7 days. Dependence was based on the number of cells remaining at the end of culture, with 300 U/mL designated as 100%. Data are from three independent experiments. IL, interleukin; iTreg, induced regulatory T cell; Kyn, kynurenines; PB, peripheral blood; Teff, effector T cell; tTreg, thymic regulatory T cell; Trp, tryptophan. Figure S8 : Ultra-low-dose IL-2 improves xenogeneric GVHD survival in mice treated with low Trp + Kyn iTregs but does not increase overall recipient survival. Ex vivo expanded tTregs and low Trp + Kyn iTregs (15 9 10 6 cells) were cotransferred with allogeneic, HLA-A2-mismatched PBMCs (15 9 10 6 cells) into non-lethally irradiated NSG mice to assess the ability to ameliorate xenogeneic GVHD. (A) Animals were bled on day 7 to determine Treg persistence by quantitating the number of human CD45 + HLA-A2 + cells expressing CD4. A cohort of mice receiving low Trp + Kyn iTregs were also given low-dose IL-2 (IP; 25 000 units/day for 14 days). Percent initial weight curves (B) and clinical scores (C) for mice receiving PBMCs plus adoptive transfer of tTregs or low Trp + Kyn iTregs. n = 8 mice per group. GVHD, graft-versus-host disease; IL, interleukin; iTreg, induced regulatory T cell; Kyn, kynurenines; PBMC, peripheral blood mononuclear cell; Teff, effector T cell; tTreg, thymic regulatory T cell; Trp, tryptophan.
